Literature DB >> 8242251

Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF.

T D Warner1, G H Allcock, R Corder, J R Vane.   

Abstract

1. We have compared the receptors mediating the contractions of rings of rat thoracic aorta or rabbit pulmonary artery and rat stomach strips in response to the endothelin/sarafotoxin (ET/SX) family of peptides and to those mediating endothelium-dependent vasodilations within the isolated perfused mesentery of the rat. To discriminate ETA receptors from ETB receptors we have used the criteria that ET-1 is more active than SX6c on ETA receptors, and that the ET/SX peptides are equiactive on ETB receptors. We have also assessed the effects of the ETA receptor-selective antagonist BQ-123, and the non-selective ET receptor antagonist PD 142893 on the responses of each preparation to the ET/SX peptides. 2. ET-1-induced constrictions of the rat thoracic aorta (EC50 3 x 10(-10) M), a prototypic ETA receptor-mediated response, or isolated perfused mesentery of the rat were antagonized by BQ-123 (10(-5) M) or PD 142893 (10(-5) M). SX6c did not constrict either the rat isolated perfused mesentery or the rat thoracic aorta. Thus, ETA receptors mediate these constrictions. 3. ET-1 and SX6c were approximately equipotent in constricting rabbit pulmonary artery rings (EC50S 3-6 x 10(-10) M). Neither BQ-123 (10(-5) M) nor PD 142893 antagonized the contractions induced by ET-1. These effects suggest mediation by ETB receptors but PD 142893 (10(-5) M) did give a 3 fold antagonism of constrictions induced by SX6c. 4. SX6c was more potent than ET-1 in contracting the rat stomach strip (threshold concentrations 10(-10) and 3 x 10(-10) M). Contractions to ET-1 or SX6c were unaffected by BQ-123 (10-5 M), again indicative of ETB receptor-mediated events. PD 142893 (10-5 M) was ineffective against ET-1 but produced a 3 fold antagonism of SX6c.5. In the rat isolated perfused mesentery ET-1 or SX6c (0.3-300pmol) were equipotent in producing dose-related vasodilatations that were unaffected by BQ-123 (10-6 M), indicative of an ETB receptor mediated response. In contrast to the other ETB-mediated responses, PD 142893 (10-6 M) strongly antagonized these vasodilatations.6. Thus, ETA receptors mediate constrictions of the rat thoracic aorta and rat isolated perfused mesentery whereas ETB receptors mediate constrictions of the rabbit pulmonary artery and rat stomach strip and endothelium-dependent dilatations within the mesentery. However, within the group of ETB receptor-mediated responses, endothelium-dependent vasodilatations are sensitive to PD 142893, whereas contractions of the isolated smooth muscle preparations are not. Thus, the receptor present on the endothelium responsible for the release of nitric oxide in response to the ET/SX peptides is most probably different from that present on smooth muscle that mediates BQ-123-insensitive contractions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8242251      PMCID: PMC2175921          DOI: 10.1111/j.1476-5381.1993.tb13879.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  THE EFFECT OF SYMPATHETIC NERVE STIMULATION OF VASOCONSTRICTOR RESPONSES IN PERFUSED MESENTERIC BLOOD VESSELS OF THE RAT.

Authors:  D D MCGREGOR
Journal:  J Physiol       Date:  1965-03       Impact factor: 5.182

2.  Specific receptors for endothelin-3 in cultured bovine endothelial cells and its cellular mechanism of action.

Authors:  T Emori; Y Hirata; F Marumo
Journal:  FEBS Lett       Date:  1990-04-24       Impact factor: 4.124

3.  Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain.

Authors:  Y Kloog; I Ambar; M Sokolovsky; E Kochva; Z Wollberg; A Bdolah
Journal:  Science       Date:  1988-10-14       Impact factor: 47.728

4.  SRTX-d, a new native peptide of the endothelin/sarafotoxin family.

Authors:  A Bdolah; Z Wollberg; G Fleminger; E Kochva
Journal:  FEBS Lett       Date:  1989-10-09       Impact factor: 4.124

5.  Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit.

Authors:  T D Warner; J A Mitchell; G de Nucci; J R Vane
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

6.  Studies with endothelin-3 and endothelin-1 on rat blood pressure and isolated tissues: evidence for multiple endothelin receptor subtypes.

Authors:  R A Spokes; M A Ghatei; S R Bloom
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

7.  Further studies on the response of the guinea-pig isolated bronchus to endothelins and sarafotoxin S6b.

Authors:  C A Maggi; S Giuliani; R Patacchini; P Santicioli; A Giachetti; A Meli
Journal:  Eur J Pharmacol       Date:  1990-01-25       Impact factor: 4.432

8.  The activity of peptides of the endothelin family in various mammalian smooth muscle preparations.

Authors:  C A Maggi; S Giuliani; R Patacchini; P Rovero; A Giachetti; A Meli
Journal:  Eur J Pharmacol       Date:  1989-12-12       Impact factor: 4.432

9.  A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity.

Authors:  K Saida; Y Mitsui; N Ishida
Journal:  J Biol Chem       Date:  1989-09-05       Impact factor: 5.157

10.  The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes.

Authors:  A Inoue; M Yanagisawa; S Kimura; Y Kasuya; T Miyauchi; K Goto; T Masaki
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

View more
  30 in total

1.  The cutaneous vasoconstrictor response to venous stasis is normal in subjects with primary Raynaud's disease.

Authors:  C M Edwards; J M Marshall; M Pugh
Journal:  Clin Auton Res       Date:  1999-10       Impact factor: 4.435

Review 2.  Endothelial modification of pulmonary vascular tone.

Authors:  N P Curzen; K B Jourdan; J A Mitchell
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

Review 3.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 4.  Vasopeptidase inhibition and endothelial function in hypertension.

Authors:  L V d'Uscio; T F Lüscher
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

5.  Regulation of the endothelin system by shear stress in human endothelial cells.

Authors:  H Morawietz; R Talanow; M Szibor; U Rueckschloss; A Schubert; B Bartling; D Darmer; J Holtz
Journal:  J Physiol       Date:  2000-06-15       Impact factor: 5.182

6.  Endothelin-1-induced contraction in isolated aortae from normotensive and DOCA-salt hypertensive rats: effect of magnesium.

Authors:  P Laurant; A Berthelot
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

7.  Necessity of dual blockade of endothelin ETA and ETB receptor subtypes for antagonism of endothelin-1-induced contraction in human bronchi.

Authors:  T Fukuroda; S Ozaki; M Ihara; K Ishikawa; M Yano; T Miyauchi; S Ishikawa; M Onizuka; K Goto; M Nishikibe
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

8.  Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065.

Authors:  T D Warner; G H Allcock; J R Vane
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

9.  Endothelin ET(B) receptors in arteries and veins: multiple actions in the vein.

Authors:  Nathan R Tykocki; Cheryl E Gariepy; Stephanie W Watts
Journal:  J Pharmacol Exp Ther       Date:  2009-03-18       Impact factor: 4.030

10.  Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists.

Authors:  G H Allcock; T D Warner; J R Vane
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.